Development of technology for the use of water-soluble C60 fullerenes to reduce skeletal muscle fatigue
Prylutskyi Yurii I., Доктор фізико-математичних наук
Taras Shevchenko National University of Kyiv
The object of research is muscle fatigue.
The purpose of the work is to find out the effect of C60 fullerenes on muscle fatigue.
The research methods are toxicological, tensometric and biochemical analyses.
As a result of toxicological studies, it was established that the value of LD50 for female and male Wistar Han rats of water-soluble C60 fullerene (0.15 mg/ml) by the oral route of entry into the body more than 15 ml/kg of body weight and in accordance with the Globally Harmonized System of Classification and Labeling of Chemicals (GHS) on the acute oral toxicity belongs to the 5th category of toxicity.
Water-soluble C60 fullerene (0.15 mg/ml) does not have a sensitizing effect on the body of ants and is not classified as a contact sensitizer in accordance with GHS requirements. Under the influence of water-soluble C60 fullerenes (0.15 mg/ml) on the body of female Wistar Han rats in doses of 0; 1.25; 3.75 and 7.50 ml/kg for 28 days, according to the recommendations of OECD 407 (OECD Guideline for Testing of Chemicals "Repeated Dose 28-day Oral Toxicity Study in Rodents"), the reliable changes in body weight and body weight gain, absolute and relative mass of internal organs were not detected. Hematological indicators of peripheral blood did not differ from controls. Reliable changes in the biochemical indicators of blood serum and urine, which characterize the functional state of the liver and kidneys, were not detected. Macroscopic research of the internal organs (brain, lungs, heart, liver, spleen, kidneys, adrenal glands, stomach, large and small intestines, thymus, lymph nodes, pancreas and thyroid glands, uterus, ovaries) did not reveal any abnormalities or pathological changes caused by exposure to water-soluble C60 fullerenes. Histological research of the brain, lungs, heart, liver, and kidneys did not reveal any changes that would indicate a harmful effect of the tested potential therapeutic agent.
Bogutska Catherine I.
Honchar Olga О.
Nozdrenko Dmytro M.
Okhramovych Mykhailo М.
Pampuha Ihor V.